Evaxion Biotech A/S Form 6-K Summary
Business context and reporting period
Evaxion Biotech A/S, a foreign private issuer headquartered in Hoersholm, Denmark, filed a Form 6-K covering April 2022. The filing was signed and filed on April 5, 2022.
Management change
Effective April 1, 2022, Niels Iversen Møller, M.D., stepped down as Chief Business Officer and Interim Chief Financial Officer. He will remain with the Company in a non-management role as Vice President of Business.
Jesper Nyegaard Nissen, the Company’s Chief Operating Officer, was appointed Interim Chief Financial Officer effective immediately upon Dr. Møller’s departure from that role. Mr. Nissen has more than 25 years of pharmaceutical-industry experience spanning finance, investments, research, and development.
Financial metrics and material changes
The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, guidance, or other financial metrics. It reports a management transition rather than operating or financial results.
Outlook, risks, and unusual items
The filing does not provide new guidance, an outlook, specific risks, contingencies, or unusual financial items. The change in Interim Chief Financial Officer is the principal reported corporate event.
Investor verification points
- Verify the effective dates and current roles of Dr. Møller and Mr. Nissen in subsequent company filings.
- Review subsequent financial filings for the Company’s cash position, financing needs, operating performance, and permanent CFO appointment.
- Note that this Form 6-K was incorporated by reference into the Company’s Form S-8 registration statement, File No. 333-255064, to the extent not superseded by later filings.